News

Cerus Quarterly Earnings Preview: What Investors Should Know

Cerus Quarterly Earnings Preview: What Investors Should Know

Cerus Quarterly Earnings Overview

Cerus CERS is all set to unveil its quarterly earnings report soon. Investors are eagerly awaiting this announcement, which is pivotal for understanding the company’s current performance and future outlook. Analysts are predicting an earnings per share (EPS) of $-0.03.

While past performance can be a useful indicator, it’s the guidance provided during the earnings call that often drives immediate market reactions. Newly interested investors should note that a company’s forecast can significantly influence share price movements.

Looking Back at Earnings Performance

In the last earnings release, Cerus exceeded EPS expectations by $0.01, resulting in a remarkable share price increase of nearly 15% the following trading day. Such performance underscores the volatility and potential rewards tied to earnings announcements.

Consider the context of Cerus’s recent earnings:

Quarterly Performance Summary:

In earlier quarters, Cerus showed varying outcomes:

  • Q2 2024: EPS Estimate: -0.04, Actual: -0.03, Price Change: +15%
  • Q1 2024: EPS Estimate: -0.05, Actual: -0.05, Price Change: -8%
  • Q4 2023: EPS Estimate: -0.02, Actual: -0.01, Price Change: +22%
  • Q3 2023: EPS Estimate: -0.05, Actual: -0.04, Price Change: +9%

Analysts' Perspectives on Cerus

It’s always essential to understand what analysts are saying about companies like Cerus, especially in such a dynamic industry. Presently, the consensus rating for Cerus is Buy, with a one-year price target around $3.0, suggesting a promising upside potential of over 74% based on current market conditions.

Comparative Analysis of Peers

In today’s market, comparing Cerus with its peers provides valuable insights. Major players such as OraSure Technologies, Rockwell Medical, and TELA Bio offer a perspective on the competitive landscape.

  • OraSure Technologies holds a Neutral outlook, with a price target of $5.0, indicating a substantial potential upside of about 190.7%.
  • In contrast, Rockwell Medical is favorably seen as a Buy with an impressive one-year price projection of $9.0, forecasting a growth of 423.26%.
  • Conversely, TELA Bio also shows a Buy consensus, with a target of $10.4, suggesting an upside of approximately 504.65%.

Key Comparisons of Market Position

When looking at key metrics, Cerus stands out in terms of revenue growth despite facing challenges in profitability. Here's a snapshot of how Cerus stacks up against its peers:

  • Cerus: Buy, Revenue Growth: 16.02%, Gross Profit: $24.67M, ROE: -11.68%
  • OraSure Technologies: Neutral, Revenue Growth: -36.41%, Gross Profit: $24.69M, ROE: -0.14%
  • Rockwell Medical: Buy, Revenue Growth: 42.88%, Gross Profit: $4.55M, ROE: 1.55%
  • TELA Bio: Buy, Revenue Growth: 11.02%, Gross Profit: $11.07M, ROE: -146.05%

The Core Mission of Cerus

Cerus Corp is dedicated to enhancing blood transfusion safety through innovative biomedical solutions. Its flagship INTERCEPT Blood System effectively mitigates the risk of rare infections associated with blood transfusions, demonstrating a commitment to public health.

Scrutinizing Cerus's Financial Metrics

Market Capitalization: Cerus's market capitalization reflects a smaller scale compared to industry averages, a critical aspect for potential investors.

Growth Rate: The company reported a revenue growth rate of approximately 16.02% for the recent quarter, outpacing many within the healthcare sector.

Margins and Returns: Despite a net margin of -12.81%, Cerus has shown effective cost management. However, its return metrics indicate challenges, with ROE and ROA lagging industry standards.

Debt Levels: With a notable debt-to-equity ratio of 1.99, Cerus must navigate its financial obligations carefully to ensure stability.

Frequently Asked Questions

1. When will Cerus release its quarterly earnings report?

The earnings report is set to be released on October 30, 2024.

2. What EPS is Cerus expected to report?

Analysts anticipate an EPS of $-0.03 for this quarter.

3. How did Cerus perform in past earnings releases?

In the previous quarter, Cerus beat estimates by $0.01, resulting in a significant share price increase.

4. What is the consensus rating for Cerus?

The consensus rating from analysts is a Buy.

5. How does Cerus compare to its peers?

Cerus performed well in revenue growth but lags in gross profit compared to its peers, indicating room for improvement in profitability.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 96

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 91

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 99

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 48

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Tech Boosts Leadership with Mike Watkinson's Appointment

Updated Category News Views 156

Future Tech Welcomes New CRO to Boost Revenue Strategy Future Tech Enterprise, Inc., a reputable provider of technology solutions, has recently appointed Mike Watkinson as its new Chief Revenue Officer (CRO). In this role, he will be responsible for driving global revenue growth and improving sales strategies for the company. This appointment follows a recent expansion of...

Continue Reading
Supporting Careers of Migraine Sufferers: AbbVie Contest Open

Updated Category News Views 250

AbbVie Launches the Second Annual Career Catalyst Award for Migraine Sufferers AbbVie has opened the entries for the second annual AbbVie Migraine Career Catalyst Award™ contest, offering significant financial assistance to help winners achieve their career aspirations. This initiative is designed to empower individuals living with migraine in their professional...

Continue Reading
Shane Neil Joins Axis Insurance as Senior VP for Eastern Canada

Updated Category News Views 116

So, Axis Insurance shook things up back when they named Shane Neil as their Senior Vice President of Corporate Development for Eastern Canada. This guy's got over 20 years in the insurance game, having kicked off his career at Chubb and moving through some heavyweight roles since then. Traders were eyeing this appointment, knowing that big names can mean bigger moves in...

Continue Reading
Water Ways Technologies Reports Q2 2024 Financial Insights

Updated Category News Views 74

Water Ways Technologies Inc. Reports Q2 2024 Financial Results Water Ways Technologies Inc. (TSXV: WWT) has released its financial results for the second quarter of 2024. As a prominent provider of agricultural technology based in Israel, the company focuses on improving water irrigation solutions and is dedicated to fostering innovation in the agriculture industry....

Continue Reading
Celebrating Technological Excellence: Mats Karlsson's Acclaimed Achievement

Updated Category News Views 116

Icomera Honors CTO Mats Karlsson with the Polhem Prize 2025 Icomera is thrilled to announce that its Chief Technology Officer, Mats Karlsson, has been awarded the Polhem Prize 2025. This esteemed recognition is one of Sweden's highest honors for outstanding contributions to technological innovation, presented by the Swedish Association of Graduate Engineers. The...

Continue Reading